Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran in Cutaneous Lupus Erythematosus (ELOWEN-1)
NCT07332481Phase 3Recruiting
- Sponsor
- EMD Serono
- Start
- Mar 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) comparing Enpatoran with Placebo (2 arms). Primary endpoint: Cutaneous Lupus Erythematosus Disease Area and Severity Index 70 Response at 24 weeks. Started Mar 2026; status: recruiting.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07332481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332481.